Tumor metabolism, the ketogenic diet and β-hydroxybutyrate: Novel approaches to adjuvant brain tumor therapy

Frontiers in Molecular Neuroscience

Volumn 9, Issue NOV2016, 2016, Pages

  Woolf, Eric C ^a,b   Syed, Nelofer ^c   Scheck, Adrienne C ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Beta hydroxybutyrate; Cancer; Glioblastoma; Glioma; Ketogenic diet; Ketones; Metabolism

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; NEUROPROTECTIVE AGENT; PLATELET DERIVED GROWTH FACTOR; POLYUNSATURATED FATTY ACID; SOMATOMEDIN; TEMOZOLOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CALORIC RESTRICTION; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; GLIOBLASTOMA; GLIOMA CELL LINE; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; KETOGENIC DIET; LIFE EXPECTANCY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; TISSUE PERFUSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84995897363     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2016.00122     Document Type: Article

References (150)

1. Abdelwahab, M. G., Fenton, K. E., Preul, M. C., Rho, J. M., Lynch, A., Stafford, P., et al. (2012). The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 7:e36197. doi: 10.1371/journal.pone.0036197
2. Abel, S., Riedel, S., and Gelderblom, W. C. A. (2014). Dietary PUFA and cancer. Proc. Nutr. Soc. 73, 361-367. doi: 10.1017/s0029665114000585
3. Allen, B. G., Bhatia, S. K., Anderson, C. M., Eichenberger-Gilmore, J. M., Sibenaller, Z. A., Mapuskar, K. A., et al. (2014). Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2, 963-970. doi: 10.1016/j.redox.2014.08.002
4. Allen, B. G., Bhatia, S. K., Buatti, J. M., Brandt, K. E., Lindholm, K. E., Button, A. M., et al. (2013). Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin. Cancer Res. 19, 3905-3913. doi: 10.1158/1078-0432.CCR-12-0287
5. Altman, B. J., Hsieh, A. L., Sengupta, A., Krishnanaiah, S. Y., Stine, Z. E., Walton, Z. E., et al. (2015). MYC disrupts the circadian clock and metabolism in cancer cells. Cell Metab. 22, 1009-1019. doi: 10.1016/j.cmet.2015.09.003
6. Amberger-Murphy, V. (2009). Hypoxia helps glioma to fight therapy. Curr. Cancer Drug Targets 9, 381-390. doi: 10.2174/156800909788166637
7. Arora, A., Singh, S., Bhatt, A. N., Pandey, S., Sandhir, R., and Dwarakanath, B. S. (2015). Interplay between metabolism and oncogenic process: role of microRNAs. Transl. Oncogenomics 7, 11-27. doi: 10.4137/TOG.S29652
8. Asati, V., Mahapatra, D. K., and Bharti, S. K. (2016). PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur. J. Med. Chem. 109, 314-341. doi: 10.1016/j.ejmech.2016.01.012
9. Barron, C. C., Bilan, P. J., Tsakiridis, T., and Tsiani, E. (2016). Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism 65, 124-139. doi: 10.1016/j.metabol.2015.10.007
10. Bishop, K. S., and Ferguson, L. R. (2015). The interaction between epigenetics, nutrition and the development of cancer. Nutrients 7, 922-947. doi: 10.3390/nu7020922
11. Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study. J. Neurooncol. 115, 87-94. doi: 10.1007/s11060-013-1198-z
12. Boroughs, L. K., and DeBerardinis, R. J. (2015). Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351-359. doi: 10.1038/ncb3124
13. Bost, F., Decoux-Poullot, A. G., Tanti, J. F., and Clavel, S. (2016). Energy disruptors: rising stars in anticancer therapy? Oncogenesis 5:e188. doi: 10.1038/oncsis.2015.46
14. Cahill, G. F. Jr., and Veech, R. L. (2003). Ketoacids? Good medicine? Trans. Am. Clin. Climatol. Assoc. 114, 149-161.
15. Cantor, J. R., and Sabatini, D. M. (2012). Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881-898. doi: 10.1158/2159-8290.CD-12-0345
16. Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., et al. (2015). Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin. Cancer Biol. 35, S199-S223. doi: 10.1016/j.semcancer.2015.02.007
17. Caso, J., Masko, E. M., Ii, J. A., Poulton, S. H., Dewhirst, M., Pizzo, S. V., et al. (2013). The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate 73, 449-454. doi: 10.1002/pros.22586
18. Champ, C. E., Baserga, R., Mishra, M. V., Jin, L., Sotgia, F., Lisanti, M. P., et al. (2013). Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist 18, 97-103. doi: 10.1634/theoncologist.2012-0164
19. Champ, C. E., Palmer, J. D., Volek, J. S., Werner-Wasik, M., Andrews, D. W., Evans, J. J., et al. (2014). Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J. Neurooncol. 117, 125-131. doi: 10.1007/s11060-014-1362-0
20. Chan, B., Manley, J., Lee, J., and Singh, S. R. (2015). The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 356, 301-308. doi: 10.1016/j.canlet.2014.10.011
21. Clark, P. M., Mai, W. X., Cloughesy, T. F., and Nathanson, D. A. (2016). Emerging approaches for targeting metabolic vulnerabilities in malignant glioma. Curr. Neurol. Neurosci. Rep. 16:17. doi: 10.1007/s11910-015-0613-6
22. Corbet, C., and Feron, O. (2015). Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer. Curr. Opin. Clin. Nutr. Metab. Care 18, 346-353. doi: 10.1097/MCO.0000000000000178
23. Courtnay, R., Ngo, D. C., Malik, N., Ververis, K., Tortorella, S. M., and Karagiannis, T. C. (2015). Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol. Biol. Rep. 42, 841-851. doi: 10.1007/s11033-015-3858-x
24. Cross, J. H. (2013). New research with diets and epilepsy. J. Child Neurol. 28, 970-974. doi: 10.1177/0883073813487593
25. Danhier, P., De Saedeleer, C. J., Karroum, O., De Preter, G., Porporato, P. E., Jordan, B. F., et al. (2013). Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications. Semin. Radiat. Oncol. 23, 262-272. doi: 10.1016/j.semradonc.2013.05.008
26. Dewhirst, M. W. (2009). Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat. Res. 172, 653-665. doi: 10.1667/RR1926.1
27. Dibble, C. C., and Cantley, L. C. (2015). Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 25, 545-555. doi: 10.1016/j.tcb.2015.06.002
28. Dirven, L., Taphoorn, M. J., Reijneveld, J. C., Blazeby, J., Jacobs, M., Pusic, A., et al. (2014). The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. Eur. J. Cancer 50, 2432-2448. doi: 10.1016/j.ejca.2014.06.016
29. Fearon, K. C., Borland, W., Preston, T., Tisdale, M. J., Shenkin, A., and Calman, K. C. (1988). Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am. J. Clin. Nutr. 47, 42-48.
30. Fischer, S., Wobben, M., Marti, H. H., Renz, D., and Schaper, W. (2002). Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc. Res. 63, 70-80. doi: 10.1006/mvre.2001.2367
31. Freedland, S. J., Mavropoulos, J., Wang, A., Darshan, M., Demark-Wahnefried, W., Aronson, W. J., et al. (2008). Carbohydrate restriction, prostate cancer growth and the insulin-like growth factor axis. Prostate 68, 11-19. doi: 10.1002/pros.20683
32. Fujiwara, S., Nakagawa, K., Harada, H., Nagato, S., Furukawa, K., Teraoka, M., et al. (2007). Silencing hypoxia-inducible factor-1α inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol. 30, 793-802. doi: 10.3892/ijo.30.4.793
33. Gano, L. B., Patel, M., and Rho, J. M. (2014). Ketogenic diets, mitochondria and neurological diseases. J. Lipid Res. 55, 2211-2228. doi: 10.1194/jlr.r048975
34. Gasior, M., Rogawski, M. A., and Hartman, A. L. (2006). Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 17, 431-439. doi: 10.1097/00008877-200609000-00009
35. Gatenby, R. A., and Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899. doi: 10.1038/nrc1478
36. Gaude, E., and Frezza, C. (2014). Defects in mitochondrial metabolism and cancer. Cancer Metab. 2:10. doi: 10.1186/2049-3002-2-10
37. Gluschnaider, U., Hertz, R., Ohayon, S., Smeir, E., Smets, M., Pikarsky, E., et al. (2014). Long-chain Fatty Acid analogues suppress breast tumorigenesis and progression. Cancer Res. 74, 6991-7002. doi: 10.1158/0008-5472.CAN-14-0385
38. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
39. Hao, G. W., Chen, Y. S., He, D. M., Wang, H. Y., Wu, G. H., and Zhang, B. (2015). Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac. J. Cancer Prev. 16, 2061-2068. doi: 10.7314/apjcp.2015.16.5.2061
40. Hartman, A. L. (2012). Neuroprotection in metabolism-based therapy. Epilepsy Res. 100, 286-294. doi: 10.1016/j.eplepsyres.2011.04.016
41. Hattingen, E., Jurcoane, A., Bähr, O., Rieger, J., Magerkurth, J., Anti, S., et al. (2011). Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 13, 1349-1363. doi: 10.1093/neuonc/nor132
42. Hayashi, Y., Edwards, N. A., Proescholdt, M. A., Oldfield, E. H., and Merrill, M. J. (2007). Regulation and function of aquaporin-1 in glioma cells. Neoplasia 9, 777-787. doi: 10.1593/neo.07454
43. Heydari, A. R., Unnikrishnan, A., Lucente, L. V., and Richardson, A. (2007). Caloric restriction and genomic stability. Nucleic Acids Res. 35, 7485-7496. doi: 10.1093/nar/gkm860
44. Hofmanova, J., Hyrslova Vaculova, A., and Kozubik, A. (2013). Regulation of the metabolism of polyunsaturated Fatty acids and butyrate in colon cancer cells. Curr. Pharm. Biotechnol. 14, 274-288. doi: 10.2174/1389201011314030004
45. Horing, E., Harter, P. N., Seznec, J., Schittenhelm, J., Buhring, H. J., Bhattacharyya, S., et al. (2012). The “go or grow” potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 124, 83-97. doi: 10.1007/s00401-011-0940-x
46. Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E., and Dang, C. V. (2015). MYC and metabolism on the path to cancer. Semin. Cell Dev. Biol. 43, 11-21. doi: 10.1016/j.semcdb.2015.08.003
47. Husain, Z., Huang, Y., Seth, P., and Sukhatme, V. P. (2013). Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486-1495. doi: 10.4049/jimmunol.1202702
48. Iurlaro, R., León-Annicchiarico, C. L., and Muñoz-Pinedo, C. (2014). Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 542, 59-80. doi: 10.1016/B978-0-12-416618-9.00003-0
49. Jaworski, D. M., Namboodiri, A. M., and Moffett, J. R. (2016). Acetate as a metabolic and epigenetic modifier of cancer therapy. J. Cell. Biochem. 117, 574-588. doi: 10.1002/jcb.25305
50. Jiang, Y.-S., and Wang, F.-R. (2013). Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J. Neurooncol. 114, 25-32. doi: 10.1007/s11060-013-1154-y
51. Joon, Y. A., Bazar, K. A., and Lee, P. Y. (2004). Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias. Med. Hypotheses 63, 352-356. doi: 10.1016/j.mehy.2004.02.026
52. Justus, C. R., Sanderlin, E. J., and Yang, L. V. (2015). Molecular connections between cancer cell metabolism and the tumor microenvironment. Int. J. Mol. Sci. 16, 11055-11086. doi: 10.3390/ijms160511055
53. Kashiwaya, Y., Bergman, C., Lee, J. H., Wan, R., King, M. T., Mughal, M. R., et al. (2013). A ketone ester diet exhibits anxiolytic and cognition-sparing properties and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease. Neurobiol. Aging 34, 1530-1539. doi: 10.1016/j.neurobiolaging.2012.11.023
54. Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., and Van Meir, E. G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 7, 134-153. doi: 10.1215/s1152851704001115
55. Kim, D. Y., Hao, J., Liu, R., Turner, G., Shi, F.-D., and Rho, J. M. (2012). Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One 7:e35476. doi: 10.1371/journal.pone.0035476
56. Kim, H. S., Masko, E. M., Poulton, S. L., Kennedy, K. M., Pizzo, S. V., Dewhirst, M. W., et al. (2012). Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 110, 1062-1069. doi: 10.1111/j.1464-410x.2012.10971.x
57. Kim, M. H., and Kim, H. (2013). Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. J. Cancer Prev. 18, 221-226. doi: 10.15430/jcp.2013.18.3.221
58. Kim, D. Y., and Rho, J. M. (2008). The ketogenic diet and epilepsy. Curr. Opin. Clin. Nutr. Metab. Care 11, 113-120. doi: 10.1097/MCO.0b013e3282f44c06
59. Klement, R. J., and Champ, C. E. (2014). Calories, carbohydrates and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev. 33, 217-229. doi: 10.1007/s10555-014-9495-3
60. Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F. M., Bianchi, G., Martin-Montalvo, A., et al. (2012). Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4:124ra127. doi: 10.1126/scitranslmed.3003293
61. Lee, C., Safdie, F. M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., et al. (2010). Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 70, 1564-1572. doi: 10.1158/0008-5472.CAN-09-3228
62. Lewis, N. E., and Abdel-Haleem, A. M. (2013). The evolution of genome-scale models of cancer metabolism. Front. Physiol. 4:237. doi: 10.3389/fphys.2013.00237
63. Lund, T. M., Risa, O., Sonnewald, U., Schousboe, A., and Waagepetersen, H. S. (2009). Availability of neurotransmitter glutamate is diminished when β-hydroxybutyrate replaces glucose in cultured neurons. J. Neurochem. 110, 80-91. doi: 10.1111/j.1471-4159.2009.06115.x
64. Lussier, D. M., Woolf, E. C., Johnson, J. L., Brooks, K. S., Blattman, J. N., and Scheck, A. C. (2016). Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16:310. doi: 10.1186/s12885-016-2337-7
65. Lv, M., Zhu, X., Wang, H., Wang, F., and Guan, W. (2014). Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One 9:e115147. doi: 10.1371/journal.pone.0115147
66. Maalouf, M., Rho, J. M., and Mattson, M. P. (2009). The neuroprotective properties of calorie restriction, the ketogenic diet and ketone bodies. Brain Res. Rev. 59, 293-315. doi: 10.1016/j.brainresrev.2008.09.002
67. Madan, E., Gogna, R., Bhatt, M., Pati, U., Kuppusamy, P., and Mahdi, A. A. (2011). Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2, 948-957. doi: 10.18632/oncotarget.389
68. Marie, S. K., and Shinjo, S. M. (2011). Metabolism and brain cancer. Clinics 66, 33-43. doi: 10.1590/s1807-59322011001300005
69. Marsh, J., Mukherjee, P., and Seyfried, T. N. (2008). Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr. Metab. (Lond) 5:33. doi: 10.1186/1743-7075-5-33
70. Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., and Hirsch, E. (2014). PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372-383. doi: 10.3109/07853890.2014.912836
71. Martuscello, R. T., Vedam-Mai, V., McCarthy, D. J., Schmoll, M. E., Jundi, M. A., Louviere, C. D., et al. (2016). A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin. Cancer Res. 22, 2482-2495. doi: 10.1158/1078-0432.CCR-15-0916
72. Masino, S. A., and Ruskin, D. N. (2013). Ketogenic diets and pain. J. Child Neurol. 28, 993-1001. doi: 10.1177/0883073813487595
73. Masson, N., and Ratcliffe, P. J. (2014). Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2:3. doi: 10.1186/2049-3002-2-3
74. Maurer, G. D., Brucker, D. P., Bähr, O., Harter, P. N., Hattingen, E., Walenta, S., et al. (2011). Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 11:315. doi: 10.1186/1471-2407-11-315
75. Mavropoulos, J. C., Buschemeyer, W. C. III, Tewari, A. K., Rokhfeld, D., Pollak, M., Zhao, Y., et al. (2009). The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev. Res. (Phila) 2, 557-565. doi: 10.1158/1940-6207.capr-08-0188
76. Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., et al. (2011). Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384. doi: 10.1038/nature10602
77. Milder, J., and Patel, M. (2012). Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res. 100, 295-303. doi: 10.1016/j.eplepsyres.2011.09.021
78. Miller, D. M., Thomas, S. D., Islam, A., Muench, D., and Sedoris, K. (2012). c-Myc and cancer metabolism. Clin. Cancer Res. 18, 5546-5553. doi: 10.1158/1078-0432.CCR-12-0977
79. Molon, B., Cali, B., and Viola, A. (2016). T cells and cancer: how metabolism shapes immunity. Front. Immunol. 7:20. doi: 10.3389/fimmu.2016.00020
80. Morris, A. A. M. (2005). Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28, 109-121. doi: 10.1007/s10545-005-5518-0
81. Mou, K., Chen, M., Mao, Q., Wang, P., Ni, R., Xia, X., et al. (2010). AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha. J. Neurooncol. 100, 375-383. doi: 10.1007/s11060-010-0205-x
82. Nebeling, L. C., and Lerner, E. (1995). Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J. Am. Diet. Assoc. 95, 693-697. doi: 10.1016/s0002-8223(95)00189-1
83. Nebeling, L. C., Miraldi, F., Shurin, S. B., and Lerner, E. (1995). Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 14, 202-208. doi: 10.1080/07315724.1995.10718495
84. Newman, J. C., and Verdin, E. (2014). Ketone bodies as signaling metabolites. Trends Endocrinol. Metab. 25, 42-52. doi: 10.1016/j.tem.2013.09.002
85. Newport, M. T., Vanitallie, T. B., Kashiwaya, Y., King, M. T., and Veech, R. L. (2015). A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s disease. Alzheimers Dement. 11, 99-103. doi: 10.1016/j.jalz.2014.01.006
86. Nicholas, M. K., Lukas, R. V., Chmura, S., Yamini, B., Lesniak, M., and Pytel, P. (2011). Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin. Oncol. 38, 243-253. doi: 10.1053/j.seminoncol.2011.01.009
87. Niyazi, M., Siefert, A., Schwarz, S. B., Ganswindt, U., Kreth, F. W., Tonn, J. C., et al. (2011). Therapeutic options for recurrent malignant glioma. Radiother. Oncol. 98, 1-14. doi: 10.1016/j.radonc.2010.11.006
88. Obre, E., and Rossignol, R. (2015). Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int. J. Biochem. Cell Biol. 59C, 167-181. doi: 10.1016/j.biocel.2014.12.008
89. Olovnikov, I. A., Kravchenko, J. E., and Chumakov, P. M. (2009). Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin. Cancer Biol. 19, 32-41. doi: 10.1016/j.semcancer.2008.11.005
90. Otto, C., Kaemmerer, U., Illert, B., Muehling, B., Pfetzer, N., Wittig, R., et al. (2008). Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 8:122. doi: 10.1186/1471-2407-8-122
91. Pavlova, N. N., and Thompson, C. B. (2016). The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27-47. doi: 10.1016/j.cmet.2015.12.006
92. Pazmandi, J., O’Neill, K. S., Scheck, A. C., Szlosarek, P. W., Woolf, E. C., Brooks, K. S., et al. (2015). Abstract 240: the ketogenic diet alters the expression of microRNAs that play key roles in tumor development. Cancer Res. 75, 240-240. doi: 10.1158/1538-7445.am2015-240
93. Pérez-Escuredo, J., Dadhich, R. K., Dhup, S., Cacace, A., Van Hée, V. F., De Saedeleer, C. J., et al. (2016). Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle 15, 72-83. doi: 10.1080/15384101.2015.1120930
94. Pifferi, F., Tremblay, S., Plourde, M., Tremblay-Mercier, J., Bentourkia, M., and Cunnane, S. C. (2008). Ketones and brain function: possible link to polyunsaturated fatty acids and availability of a new brain PET tracer, 11C-acetoacetate. Epilepsia 49, 76-79. doi: 10.1111/j.1528-1167.2008.01842.x
95. Poff, A. M., Ari, C., Arnold, P., Seyfried, T. N., and D’Agostino, D. P. (2014). Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int. J. Cancer 135, 1711-1720. doi: 10.1002/ijc.28809
96. Poff, A. M., Ari, C., Seyfried, T. N., and D’Agostino, D. P. (2013). The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One 8:e65522. doi: 10.1371/journal.pone.0065522
97. Poff, A. M., Ward, N., Seyfried, T. N., Arnold, P., and D’Agostino, D. P. (2015). Non-toxic metabolic management of metastatic cancer in vm mice: novel combination of ketogenic diet, ketone supplementation and hyperbaric oxygen therapy. PLoS One 10:e0127407. doi: 10.1371/journal.pone.0127407
98. Pore, N., Jiang, Z., Shu, H. K., Bernhard, E., Kao, G. D., and Maity, A. (2006). Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol. Cancer Res. 4, 471-479. doi: 10.1158/1541-7786.mcr-05-0234
99. Proescholdt, M. A., Merrill, M. J., Stoerr, E. M., Lohmeier, A., Pohl, F., and Brawanski, A. (2012). Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol. 14, 1357-1366. doi: 10.1093/neuonc/nos216
100. Puchowicz, M. A., Zechel, J. L., Valerio, J., Emancipator, D. S., Xu, K., Pundik, S., et al. (2008). Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J. Cereb. Blood Flow Metab. 28, 1907-1916. doi: 10.1038/jcbfm.2008.79
101. Puzio-Kuter, A. M. (2011). The role of p53 in metabolic regulation. Genes Cancer 2, 385-391. doi: 10.1177/1947601911409738
102. Raffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., et al. (2008). Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. U S A 105, 8215-8220. doi: 10.1073/pnas.0708100105
103. Raffaghello, L., Safdie, F., Bianchi, G., Dorff, T., Fontana, L., and Longo, V. D. (2010). Fasting and differential chemotherapy protection in patients. Cell Cycle 9, 4474-4476. doi: 10.4161/cc.9.22.13954
104. Rahman, M., Muhammad, S., Khan, M. A., Chen, H., Ridder, D. A., Müller-Fielitz, H., et al. (2014). The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat. Commun. 5:3944. doi: 10.1038/ncomms4944
105. Roberts, D. J., and Miyamoto, S. (2015). Hexokinase II integrates energy metabolism and cellular protection: akting on mitochondria and TORCing to autophagy. Cell Death Differ. 22, 248-257. doi: 10.1038/cdd.2014.173
106. Robey, R. B., and Hay, N. (2009). Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25-31. doi: 10.1016/j.semcancer.2008.11.010
107. Robey, R. B., Weisz, J., Kuemmerle, N. B., Salzberg, A. C., Berg, A., Brown, D. G., et al. (2015). Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? Carcinogenesis 36, S203-S231. doi: 10.1093/carcin/bgv037
108. Roesler, R., Brunetto, A. T., Abujamra, A. L., de Farias, C. B., Brunetto, A. L., and Schwartsmann, G. (2010). Current and emerging molecular targets in glioma. Expert. Rev Anticancer Ther. 10, 1735-1751. doi: 10.1586/era.10.167
109. Rossi, A. P., Woolf, E. C., Brooks, K. S., Fairres, M. J., and Scheck, A. C. (2015). Abstract 3346: the ketone body β-hydroxybutyrate increases radiosensitivity in glioma cell lines in vitro. Cancer Res. 75:3346. doi: 10.1158/1538-7445.am2015-3346
110. Safdie, F., Brandhorst, S., Wei, M., Wang, W., Lee, C., Hwang, S., et al. (2012). Fasting enhances the response of glioma to chemo-and radiotherapy. PLoS One 7:e44603. doi: 10.1371/journal.pone.0044603
111. Saleh, A. D., Simone, B. A., Palazzo, J., Savage, J. E., Sano, Y., Dan, T., et al. (2013). Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 12, 1955-1963. doi: 10.4161/cc.25016
112. Santivasi, W. L., and Xia, F. (2014). Ionizing radiation-induced DNA damage, response and repair. Antioxid. Redox Signal. 21, 251-259. doi: 10.1089/ars.2013.5668
113. Sauer, L. A., Blask, D. E., and Dauchy, R. T. (2007). Dietary factors and growth and metabolism in experimental tumors. J. Nutr. Biochem. 18, 637-649. doi: 10.1016/j.jnutbio.2006.12.009
114. Scheck, A. C., Abdelwahab, M. G., Fenton, K., and Stafford, P. (2012). The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res. 100, 327-337. doi: 10.1016/j.eplepsyres.2011.09.022
115. Scheck, A. C., Abdelwahab, M. G., Stafford, P., Kim, D. Y., Iwai, S., Preul, M. C., et al. (2011). Abstract 638: mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. Cancer Res. 70, 638-638. doi: 10.1158/1538-7445.am10-638
116. Schmidt, M., Pfetzer, N., Schwab, M., Strauss, I., and Kammerer, U. (2011). Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr. Metab. (Lond) 8:54. doi: 10.1186/1743-7075-8-54
117. Schwartz, K., Chang, H. T., Nikolai, M., Pernicone, J., Rhee, S., Olson, K., et al. (2015). Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 3:3. doi: 10.1186/s40170-015-0129-1
118. Semenza, G. L. (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest 123, 3664-3671. doi: 10.1172/JCI67230
119. Seyfried, T. N. (2012). Cancer as a Metabolic Disease: On the Origin, Management and Prevention of Cancer. Hoboken, NJ: John Wiley and Sons, Inc.
120. Seyfried, T. N., Kiebish, M. A., Marsh, J., Shelton, L. M., Huysentruyt, L. C., and Mukherjee, P. (2011). Metabolic management of brain cancer. Biochim. Biophys. Acta 1807, 577-594. doi: 10.1016/j.bbabio.2010.08.009
121. Seyfried, T. N., and Mukherjee, P. (2005). Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. (Lond) 2:30. doi: 10.1186/1743-7075-2-30
122. Shelton, L. M., Huysentruyt, L. C., Mukherjee, P., and Seyfried, T. N. (2010). Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro 2:e00038. doi: 10.1042/AN20100002
123. Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., et al. (2013). Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211-214. doi: 10.1126/science.1227166
124. Shukla, S. K., Gebregiworgis, T., Purohit, V., Chaika, N. V., Gunda, V., Radhakrishnan, P., et al. (2014). Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2:18. doi: 10.1186/2049-3002-2-18
125. Silva-Nichols, H. B., Woolf, E. C., Deleyrolle, L. P., Reynolds, B. A., and Scheck, A. C. (2015). The ketone body β-hydroxybutyrate radiosensitizes glioblastoma multiforme stem cells. Neuro Oncol. 17:v35. doi: 10.1093/neuonc/nov204.77
126. Simone, B. A., Champ, C. E., Rosenberg, A. L., Berger, A. C., Monti, D. A., Dicker, A. P., et al. (2013). Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol. 9, 959-976. doi: 10.2217/fon.13.31
127. Skinner, R., Trujillo, A., Ma, X., and Beierle, E. A. (2009). Ketone bodies inhibit the viability of human neuroblastoma cells. J. Pediatr. Surg. 44, 212-216. doi: 10.1016/j.jpedsurg.2008.10.042
128. Stafford, P., Abdelwahab, M. G., Kim, D. Y., Preul, M. C., Rho, J. M., and Scheck, A. C. (2010). The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr. Metab. (Lond) 7:74. doi: 10.1186/1743-7075-7-74
129. Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., and Dang, C. V. (2015). MYC, metabolism and cancer. Cancer Discov. 5, 1024-1039. doi: 10.1158/2159-8290.CD-15-0507
130. Tisdale, M. J., and Brennan, R. A. (1983). Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br. J. Cancer 47, 293-297. doi: 10.1038/bjc.1983.38
131. Tisdale, M. J., Brennan, R. A., and Fearon, K. C. (1987). Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br. J. Cancer 56, 39-43. doi: 10.1038/bjc.1987.149
132. van den Bent, M. J., Wefel, J. S., Schiff, D., Taphoorn, M. J., Jaeckle, K., Junck, L., et al. (2011). Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12, 583-593. doi: 10.1016/s1470-2045(11)70057-2
133. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033. doi: 10.1126/science.1160809
134. Vanitallie, T. B., and Nufert, T. H. (2003). Ketones: metabolism’s ugly duckling. Nutr. Rev. 61, 327-341. doi: 10.1301/nr.2003.oct.327-341
135. Veech, R. L. (2004). The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 70, 309-319. doi: 10.1016/j.plefa.2003.09.007
136. Veech, R. L. (2014). Ketone ester effects on metabolism and transcription. J. Lipid Res. 55, 2004-2006. doi: 10.1194/jlr.r046292
137. Veech, R. L., Chance, B., Kashiwaya, Y., Lardy, H. A., and Cahill, G. F. Jr. (2001). Ketone bodies, potential therapeutic uses. IUBMB Life 51, 241-247. doi: 10.1080/152165401753311780
138. Wang, Q., Hu, M., Xu, H., and Yang, X. (2016). Anti-inflammatory and pro-resolving effects of N-3 PUFA in cancers: structures and mechanisms. Curr. Top. Med. Chem. 16, 888-894. doi: 10.2174/1568026615666150827101602
139. Wang, J., Luo, T., Li, S., and Zhao, J. (2012). The powerful applications of polyunsaturated fatty acids in improving the therapeutic efficacy of anticancer drugs. Expert Opin. Drug Deliv. 9, 1-7. doi: 10.1517/17425247.2011.618183
140. Warburg, O., Wind, F., and Negelein, E. (1927). The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530. doi: 10.1085/jgp.8.6.519
141. Ward, P. S., and Thompson, C. B. (2012). Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308. doi: 10.1016/j.ccr.2012.02.014
142. Wei, W., Shi, Q., Remacle, F., Qin, L., Shackelford, D. B., Shin, Y. S., et al. (2013). Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proc. Natl. Acad. Sci. U S A 110, E1352-E1360. doi: 10.1073/pnas.1303060110
143. Woolf, E. C., Curley, K. L., Liu, Q., Turner, G. H., Charlton, J. A., Preul, M. C., et al. (2015). The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One 10:e0130357. doi: 10.1371/journal.pone.0130357
144. Yamada, M., Tomida, A., Yun, J., Cai, B., Yoshikawa, H., Taketani, Y., et al. (1999). Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother. Pharmacol. 44, 59-64. doi: 10.1007/s002800050945
145. Yang, L., Lin, C., Wang, L., Guo, H., and Wang, X. (2012). Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp. Cell Res. 318, 2417-2426. doi: 10.1016/j.yexcr.2012.07.017
146. Yang, C., Sudderth, J., Dang, T., Bachoo, R. G., McDonald, J. G., and DeBerardinis, R. J. (2009). Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69, 7986-7993. doi: 10.1158/0008-5472.CAN-09-2266
147. Youm, Y. H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., et al. (2015). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263-269. doi: 10.1038/nm.3804
148. Zhou, W., Mukherjee, P., Kiebish, M. A., Markis, W. T., Mantis, J. G., and Seyfried, T. N. (2007). The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. (Lond) 4:5. doi: 10.1186/1743-7075-4-5
149. Zuccoli, G., Marcello, N., Pisanello, A., Servadei, F., Vaccaro, S., Mukherjee, P., et al. (2010). Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr. Metab. (Lond) 7:33. doi: 10.1186/1743-7075-7-33
150. Zwaans, B. M., and Lombard, D. B. (2014). Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis. Model. Mech. 7, 1023-1032. doi: 10.1242/dmm.016287